[
  {
    "ts": null,
    "headline": "Merck Poised for Mid-Single-Digit Revenue Growth in Fiscal 2026, BofA Says",
    "summary": "Merck (MRK) is expected to deliver mid-single-digit revenue growth in fiscal 2026 driven primarily b",
    "url": "https://finnhub.io/api/news?id=1b3bb87ee78163206725600df5bcb2e90139c83cf876e4e2c317fbcd545785ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765815245,
      "headline": "Merck Poised for Mid-Single-Digit Revenue Growth in Fiscal 2026, BofA Says",
      "id": 137795379,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) is expected to deliver mid-single-digit revenue growth in fiscal 2026 driven primarily b",
      "url": "https://finnhub.io/api/news?id=1b3bb87ee78163206725600df5bcb2e90139c83cf876e4e2c317fbcd545785ff"
    }
  },
  {
    "ts": null,
    "headline": "MRK Gets Positive CHMP Opinion for Expanded Use of Winrevair in PAH",
    "summary": "Merck secures a positive CHMP opinion to expand Winrevair's PAH use, potentially broadening treatment to adult patients across WHO FC II-IV.",
    "url": "https://finnhub.io/api/news?id=9b8dfb9692d98bb0f8e473627fd4622ed1717583afe48fe2b0c16eb7379c474a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765810200,
      "headline": "MRK Gets Positive CHMP Opinion for Expanded Use of Winrevair in PAH",
      "id": 137795319,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck secures a positive CHMP opinion to expand Winrevair's PAH use, potentially broadening treatment to adult patients across WHO FC II-IV.",
      "url": "https://finnhub.io/api/news?id=9b8dfb9692d98bb0f8e473627fd4622ed1717583afe48fe2b0c16eb7379c474a"
    }
  },
  {
    "ts": null,
    "headline": "BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?",
    "summary": "BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.",
    "url": "https://finnhub.io/api/news?id=1d4a90b0200d0f97c62ae38bef46dd9a306144d0cf979a0704ceb7ef8d7748a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765809120,
      "headline": "BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?",
      "id": 137792667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.",
      "url": "https://finnhub.io/api/news?id=1d4a90b0200d0f97c62ae38bef46dd9a306144d0cf979a0704ceb7ef8d7748a0"
    }
  },
  {
    "ts": null,
    "headline": "LGND: 2025 Analyst Day",
    "summary": "By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its 2025 analyst day on December 9 th , 2025, at the Harvard Club in New York City. The morning presentations highlighted the company’s achievements for 2025 and looked ahead to 2026, providing financial guidance for the next year. Details of the event are included in a press",
    "url": "https://finnhub.io/api/news?id=1f7447cd842cfe4a3601760d357ed9d56ea9f5190560e43721f3f1db4c35126b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765796640,
      "headline": "LGND: 2025 Analyst Day",
      "id": 137795382,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its 2025 analyst day on December 9 th , 2025, at the Harvard Club in New York City. The morning presentations highlighted the company’s achievements for 2025 and looked ahead to 2026, providing financial guidance for the next year. Details of the event are included in a press",
      "url": "https://finnhub.io/api/news?id=1f7447cd842cfe4a3601760d357ed9d56ea9f5190560e43721f3f1db4c35126b"
    }
  }
]